Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Brunner

Showing results (731-740 of 792) with videos related to

Pageof 80
Sort By:
The Journal of Allergy and Clinical Immunology|September 28, 2016
Early-onset pediatric atopic dermatitis is T<sub>H</sub>2 but also T<sub>H</sub>17 polarized in skinHitokazu Esaki, Patrick M Brunner, Yael Renert-Yuval, et al.
Molecular Neurodegeneration|October 15, 2025
Modeling neurodegeneration in the retina and strategies for developing pan-neurodegenerative therapiesEmily L Ward, Larry Benowitz, Thomas M Brunner, et al.
Blood Cancer Journal|November 1, 2024
Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimenShai Shimony, Hari S Raman, Yael Flamand, et al.
Blood Advances|June 30, 2026
A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMMLAndrew M Brunner, Yiwen Liu, Jacqueline S Garcia, et al.
British Journal of Haematology|July 20, 2016
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remissionAndrew M Brunner, Shuli Li, Amir T Fathi, et al.
Leukemia|January 3, 2022
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blastsDavid M Swoboda, Rashmi Kanagal-Shamanna, Andrew M Brunner, et al.
Blood Advances|September 23, 2022
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignanciesAmir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
JAMA Oncology|December 17, 2020
Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical TrialAreej El-Jawahri, Thomas W LeBlanc, Alison Kavanaugh, et al.
British Journal of Haematology|July 13, 2026
Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemiaCatherine Gutierrez Moore, Donian I Chyong, Naval Daver, et al.
Haematologica|August 5, 2021
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative studySabine Kayser, Michael Kramer, David Martínez-Cuadrón, et al.
Pageof 80

Showing results (731-740 of 792) with videos related to

Sort By:
Pageof 80
The Journal of Allergy and Clinical Immunology|September 28, 2016
Early-onset pediatric atopic dermatitis is T<sub>H</sub>2 but also T<sub>H</sub>17 polarized in skinHitokazu Esaki, Patrick M Brunner, Yael Renert-Yuval, et al.
Molecular Neurodegeneration|October 15, 2025
Modeling neurodegeneration in the retina and strategies for developing pan-neurodegenerative therapiesEmily L Ward, Larry Benowitz, Thomas M Brunner, et al.
Blood Cancer Journal|November 1, 2024
Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimenShai Shimony, Hari S Raman, Yael Flamand, et al.
Blood Advances|June 30, 2026
A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMMLAndrew M Brunner, Yiwen Liu, Jacqueline S Garcia, et al.
British Journal of Haematology|July 20, 2016
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remissionAndrew M Brunner, Shuli Li, Amir T Fathi, et al.
Leukemia|January 3, 2022
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blastsDavid M Swoboda, Rashmi Kanagal-Shamanna, Andrew M Brunner, et al.
Blood Advances|September 23, 2022
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignanciesAmir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
JAMA Oncology|December 17, 2020
Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical TrialAreej El-Jawahri, Thomas W LeBlanc, Alison Kavanaugh, et al.
British Journal of Haematology|July 13, 2026
Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemiaCatherine Gutierrez Moore, Donian I Chyong, Naval Daver, et al.
Haematologica|August 5, 2021
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative studySabine Kayser, Michael Kramer, David Martínez-Cuadrón, et al.
Pageof 80